Browse SPRY2

Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Cell projection, ruffle membrane Note=Associated with microtubules in unstimulated cells but is translocated to the membrane ruffles in cells stimulated ith EGF (epidermal growth factor).
Domain PF05210 Sprouty protein (Spry)
Function

May function as an antagonist of fibroblast growth factor (FGF) pathways and may negatively modulate respiratory organogenesis.

> Gene Ontology
 
Biological Process GO:0000132 establishment of mitotic spindle orientation
GO:0000226 microtubule cytoskeleton organization
GO:0001763 morphogenesis of a branching structure
GO:0001933 negative regulation of protein phosphorylation
GO:0003401 axis elongation
GO:0006469 negative regulation of protein kinase activity
GO:0007163 establishment or maintenance of cell polarity
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007265 Ras protein signal transduction
GO:0007423 sensory organ development
GO:0007605 sensory perception of sound
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0010799 regulation of peptidyl-threonine phosphorylation
GO:0010801 negative regulation of peptidyl-threonine phosphorylation
GO:0018105 peptidyl-serine phosphorylation
GO:0018107 peptidyl-threonine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018210 peptidyl-threonine modification
GO:0030010 establishment of cell polarity
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0031345 negative regulation of cell projection organization
GO:0033135 regulation of peptidyl-serine phosphorylation
GO:0033138 positive regulation of peptidyl-serine phosphorylation
GO:0033673 negative regulation of kinase activity
GO:0033674 positive regulation of kinase activity
GO:0034260 negative regulation of GTPase activity
GO:0035239 tube morphogenesis
GO:0035265 organ growth
GO:0038127 ERBB signaling pathway
GO:0038179 neurotrophin signaling pathway
GO:0040001 establishment of mitotic spindle localization
GO:0040036 regulation of fibroblast growth factor receptor signaling pathway
GO:0040037 negative regulation of fibroblast growth factor receptor signaling pathway
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway
GO:0042326 negative regulation of phosphorylation
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0043405 regulation of MAP kinase activity
GO:0043407 negative regulation of MAP kinase activity
GO:0043409 negative regulation of MAPK cascade
GO:0043410 positive regulation of MAPK cascade
GO:0043491 protein kinase B signaling
GO:0043583 ear development
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0045165 cell fate commitment
GO:0045860 positive regulation of protein kinase activity
GO:0046578 regulation of Ras protein signal transduction
GO:0046580 negative regulation of Ras protein signal transduction
GO:0048011 neurotrophin TRK receptor signaling pathway
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048839 inner ear development
GO:0050954 sensory perception of mechanical stimulus
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051058 negative regulation of small GTPase mediated signal transduction
GO:0051293 establishment of spindle localization
GO:0051294 establishment of spindle orientation
GO:0051346 negative regulation of hydrolase activity
GO:0051348 negative regulation of transferase activity
GO:0051386 regulation of neurotrophin TRK receptor signaling pathway
GO:0051387 negative regulation of neurotrophin TRK receptor signaling pathway
GO:0051640 organelle localization
GO:0051653 spindle localization
GO:0051656 establishment of organelle localization
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0060425 lung morphogenesis
GO:0060437 lung growth
GO:0060441 epithelial tube branching involved in lung morphogenesis
GO:0060449 bud elongation involved in lung branching
GO:0060541 respiratory system development
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060602 branch elongation of an epithelium
GO:0061138 morphogenesis of a branching epithelium
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070373 negative regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0071774 response to fibroblast growth factor
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:0090596 sensory organ morphogenesis
GO:1901184 regulation of ERBB signaling pathway
GO:1901185 negative regulation of ERBB signaling pathway
GO:1902532 negative regulation of intracellular signal transduction
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0008047 enzyme activator activity
GO:0019207 kinase regulator activity
GO:0019209 kinase activator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
GO:0030291 protein serine/threonine kinase inhibitor activity
GO:0030295 protein kinase activator activity
GO:0043539 protein serine/threonine kinase activator activity
Cellular Component GO:0001726 ruffle
GO:0005874 microtubule
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0032587 ruffle membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-182971: EGFR downregulation
R-HSA-5654726: Negative regulation of FGFR1 signaling
R-HSA-5654727: Negative regulation of FGFR2 signaling
R-HSA-5654732: Negative regulation of FGFR3 signaling
R-HSA-5654733: Negative regulation of FGFR4 signaling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-190236: Signaling by FGFR
R-HSA-5654736: Signaling by FGFR1
R-HSA-5654738: Signaling by FGFR2
R-HSA-5654741: Signaling by FGFR3
R-HSA-5654743: Signaling by FGFR4
R-HSA-1295596: Spry regulation of FGF signaling
Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SPRY2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SPRY2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29635363gliomaInhibit immunityThe present study highlights an antitumoral effect of SPRY2 inhibition that is based on excessive activation of ERK signaling and DNA damage response, resulting in reduced cell proliferation and increased cytotoxicity, proposing SPRY2 as a promising pharmacological target in GBM patients.
Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SPRY2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SPRY2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1510.745
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3590.891
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0080.996
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1820.706
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2090.906
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1410.944
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3940.46
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4270.816
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2170.906
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2790.788
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.720.629
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4240.00209
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SPRY2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SPRY2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SPRY2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SPRY2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SPRY2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SPRY2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SPRY2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSPRY2
Namesprouty RTK signaling antagonist 2
Aliases hSPRY2; sprouty homolog 2 (Drosophila); sprouty 2; sprouty homolog 2; spry-2; Protein sprouty homolog 2
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SPRY2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.